C97 Financial Statements From 2010 to 2026
| C97 Stock | EUR 5.16 0.00 0.00% |
Check Co Diagnostics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Co Diagnostics' main balance sheet or income statement drivers, such as , as well as many indicators such as . C97 financial statements analysis is a perfect complement when working with Co Diagnostics Valuation or Volatility modules.
C97 |
Co Diagnostics Company Operating Margin Analysis
Co Diagnostics' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Co Diagnostics Operating Margin | 52.10 % |
Most of Co Diagnostics' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Co Diagnostics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Co Diagnostics has an Operating Margin of 52%. This is 248.52% lower than that of the Healthcare sector and 182.23% lower than that of the Diagnostics & Research industry. The operating margin for all Germany stocks is notably lower than that of the firm.
Co Diagnostics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Co Diagnostics's current stock value. Our valuation model uses many indicators to compare Co Diagnostics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Co Diagnostics competition to find correlations between indicators driving Co Diagnostics's intrinsic value. More Info.Co Diagnostics is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.63 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Co Diagnostics is roughly 1.58 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Co Diagnostics' earnings, one of the primary drivers of an investment's value.About Co Diagnostics Financial Statements
Co Diagnostics stakeholders use historical fundamental indicators, such as Co Diagnostics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Co Diagnostics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Co Diagnostics' assets and liabilities are reflected in the revenues and expenses on Co Diagnostics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Co Diagnostics. Please read more on our technical analysis and fundamental analysis pages.
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection andor analysis of nucleic acid molecules. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah. CO DIAGNOSTICS operates under Diagnostics Research classification in Germany and is traded on Frankfurt Stock Exchange. It employs people.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in C97 Stock
When determining whether Co Diagnostics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Co Diagnostics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Co Diagnostics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Co Diagnostics Stock:Check out the analysis of Co Diagnostics Correlation against competitors. For more detail on how to invest in C97 Stock please use our How to Invest in Co Diagnostics guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.